PCSK9 & Statins: Lowering LDL After Heart Transplant
Nearly 40% of heart transplant recipients experience significant hypercholesterolemia within five years post-transplant, despite standard statin therapy. This alarming statistic underscores a critical gap in care and a growing need for innovative approaches. Now, emerging data suggests a powerful combination therapy – PCSK9 inhibitors alongside statins – could fundamentally alter the landscape of post-transplant cardiovascular … Read more